CoChat

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety

García-Gutiérrez, Valentín, Hernández-Boluda, Juan Carlos · 2019 · Frontiers in Oncology
Cited by 134

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2019.00603

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 81

  1. Hochhaus, 2017, Long-term outcomes of imatinib treatment for chronic myeloid leukemia, N Engl J Med., 376, 917, 10.1056/NEJMoa1609324 · DOI · Paper page
  2. Sasaki, 2015, Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials, Lancet Haematol., 2, e186, 10.1016/S2352-3026(15)00048-4 · DOI · Paper page
  3. Mughal, 2016, Chronic myeloid leukemia: reminiscences and dreams, Haematologica., 101, 541, 10.3324/haematol.2015.139337 · DOI
  4. Baccarani, 2017, Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence, Leukemia., 31, 1015, 10.1038/leu.2017.20 · DOI
  5. Baccarani, 2013, European leukemianet recommendations for the management of chronic myeloid leukemia: 2013, Blood., 122, 872, 10.1182/blood-2013-05-501569 · DOI · Paper page
  6. Kantarjian, 2002, Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia, N Engl J Med., 346, 645, 10.1056/NEJMoa011573 · DOI · Paper page
  7. O'Brien, 2003, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia, N Engl J Med., 348, 994, 10.1056/NEJMoa022457 · DOI · Paper page
  8. Gugliotta, 2015, Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia, Haematologica., 100, 1146, 10.3324/haematol.2015.129221 · DOI
  9. Viganò, 2014, First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis, Am J Hematol., 89, E184, 10.1002/ajh.23804 · doi:10.1002/ajh.23804
  10. Druker, 2001, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, N Engl J Med., 344, 1031, 10.1056/NEJM200104053441401 · DOI · Paper page
  11. Liu, 2016, Clinical efficacy and safety of high-dose imatinib for chronic myeloid leukemia patients: an updated meta-analysis, J Cancer Res Ther., 12, 23, 10.4103/0973-1482.191623 · doi:10.4103/0973-1482.191623
  12. Cortes, 2010, Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia, J Clin Oncol Off J Am Soc Clin Oncol., 28, 398, 10.1200/JCO.2009.25.4920 · DOI · Paper page
  13. Kantarjian, 2012, Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION), Blood., 119, 1123, 10.1182/blood-2011-08-376087 · DOI · Paper page
  14. Naqvi, 2018, Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia, Cancer., 124, 2740, 10.1002/cncr.31357 · DOI · Paper page
  15. Rosti, 2009, Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia, Blood., 114, 4933, 10.1182/blood-2009-07-232595 · DOI · Paper page
  16. Cortes, 2010, Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase, J Clin Oncol Off J Am Soc Clin Oncol., 28, 392, 10.1200/JCO.2009.25.4896 · DOI · Paper page
  17. Saglio, 2010, Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia, N Engl J Med., 362, 2251, 10.1056/NEJMoa0912614 · DOI · Paper page
  18. Hochhaus, 2016, Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial, Leukemia., 30, 1044, 10.1038/leu.2016.5 · DOI · Paper page
  19. Konig, 2008, Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606, Blood., 111, 2329, 10.1182/blood-2007-05-092056 · DOI
  20. Cortes, 2011, Safety and efficacy of bosutinib (SKI-606) in chronic phase philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib, Blood., 118, 4567, 10.1182/blood-2011-05-355594 · DOI · Paper page
  21. Khoury, 2012, Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure, Blood., 119, 3403, 10.1182/blood-2011-11-390120 · DOI · Paper page
  22. Cortes, 2012, Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial, J Clin Oncol Off J Am Soc Clin Oncol., 30, 3486, 10.1200/JCO.2011.38.7522 · DOI · Paper page
  23. Cortes, 2018, Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial, J Clin Oncol Off J Am Soc Clin Oncol., 36, 231, 10.1200/JCO.2017.74.7162 · DOI · Paper page
  24. Gugliotta, 2013, Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors, Expert Rev Hematol., 6, 563, 10.1586/17474086.2013.837279 · DOI
  25. Sacha, 2017, A multicenter prospective study on efficacy and safety of imatinib generics: a report from polish adult leukemia group imatinib generics registry, Am J Hematol., 92, E125, 10.1002/ajh.24748 · doi:10.1002/ajh.24748
  26. Claudiani, 2018, The argument for using imatinib in CML, Hematol Am Soc Hematol Educ Program., 2018, 161, 10.1182/asheducation-2018.1.161 · DOI · Paper page
  27. Breccia, 2016, Early molecular response in chronic myeloid leukemia and halving time: latest evidences, Leuk Res., 48, 20, 10.1016/j.leukres.2016.06.010 · doi:10.1016/j.leukres.2016.06.010
  28. Radich, 2018, Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology, J Natl Compr Cancer Netw JNCCN., 16, 1108, 10.6004/jnccn.2018.0071 · DOI · Paper page
  29. Hochhaus, 2018, Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol Off J Eur Soc Med Oncol., 10.1093/annonc/mdy159 · doi:10.1093/annonc/mdy159
  30. Saglio, 2018, Considerations for treatment-free remission in patients with chronic myeloid leukemia: a joint patient-physician perspective, Clin Lymphoma Myeloma Leuk., 18, 375, 10.1016/j.clml.2018.04.005 · DOI
  31. Hijiya, 2019, How I treat chronic myeloid leukemia in children and adolescents, Blood., 133, 2374, 10.1182/blood.2018882233 · DOI
  32. Cortes, 2019, Treatment-free remission with first- and second-generation tyrosine kinase inhibitors, Am J Hematol., 94, 346, 10.1002/ajh.25342 · DOI · Paper page
  33. Fava, 2019, Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice, Haematologica., 10.3324/haematol.2018.205054 · DOI · Paper page
  34. Shah, 2014, Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study, Blood., 123, 2317, 10.1182/blood-2013-10-532341 · DOI · Paper page
  35. Giles, 2013, Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study, Leukemia., 27, 107, 10.1038/leu.2012.181 · DOI · Paper page
  36. Gambacorti-Passerini, 2018, Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study, Haematologica., 103, 1298, 10.3324/haematol.2017.171249 · DOI
  37. Tiribelli, 2018, Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients, Oncotarget., 9, 14219, 10.18632/oncotarget.24478 · DOI
  38. Cortes, 2018, Dasatinib versus imatinib in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: dascern study, Blood., 132, 788, 10.1182/blood-2018-99-111978 · doi:10.1182/blood-2018-99-111978
  39. Cortes, 2016, Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial, Lancet Haematol., 3, e581, 10.1016/S2352-3026(16)30167-3 · DOI
  40. Garcia-Gutierrez, 2016, Safety and efficacy of dasatinib treatment change for patients previosly treated with imatinib with late warning response. Results from the phase II, open, multicenter dasapost study, Blood., 128, 5450, 10.1182/blood.V128.22.5450.5450 · doi:10.1182/blood.v128.22.5450.5450
  41. Hughes, 2017, Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results, Leukemia., 31, 2529, 10.1038/leu.2017.247 · DOI
  42. Rea, 2016, ENESTPath: a phase 3 study to assess the effect of nilotinib treatment duration on treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CMLCP) previously treated with imatinib: 24-month. Analysis of the first 300 patients in the induction/consolidation phase, Blood., 128, 3094, 10.1182/blood.V128.22.3094.3094 · doi:10.1182/blood.v128.22.3094.3094
  43. Cortes, 2016, Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH study, Clin Lymphoma Myeloma Leuk., 16, 286, 10.1016/j.clml.2016.02.002 · DOI
  44. Hiwase, 2018, Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: results from the phase IIIb ENESTswift study, Leuk Res., 67, 109, 10.1016/j.leukres.2018.02.013 · DOI
  45. Cortes, 2011, Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib, Blood., 117, 5600, 10.1182/blood-2010-11-318949 · DOI
  46. Gambacorti Passerini, 2018, Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with philadelphia chromosome–positive (Ph+) leukemia: phase 1/2 study update, J Clin Oncol Off J Am Soc Clin Oncol., 36, 7062, 10.1200/JCO.2018.36.15_suppl.7062 · doi:10.1200/jco.2018.36.15_suppl.7062
  47. Giles, 2010, Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy, Leukemia., 24, 1299, 10.1038/leu.2010.110 · DOI · Paper page
  48. Cortes, 2016, Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib, Am J Hematol., 91, 1206, 10.1002/ajh.24536 · DOI · Paper page
  49. García-Gutiérrez, 2019, Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients, Ann Hematol., 98, 321, 10.1007/s00277-018-3507-2 · DOI
  50. Cortes, 2013, A phase 2 trial of ponatinib in philadelphia chromosome-positive leukemias, N Engl J Med., 369, 1783, 10.1056/NEJMoa1306494 · DOI · Paper page
  51. Cortes, 2018, Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial, Blood., 132, 393, 10.1182/blood-2016-09-739086 · DOI · Paper page
  52. Jain, 2016, Analysis of 2013 european leukaemianet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes, Br J Haematol., 173, 114, 10.1111/bjh.13936 · DOI
  53. Lipton, 2015, Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors, Leuk Res., 39, 58, 10.1016/j.leukres.2014.10.005 · DOI
  54. Breccia, 2018, Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice, Ann Hematol., 97, 1577, 10.1007/s00277-018-3337-2 · doi:10.1007/s00277-018-3337-2
  55. Tefferi, 2018, Upfront low-dose ponatinib (15 mg/day) for multi-TKI resistant chronic myeloid leukemia, Hematol Oncol., 36, 718, 10.1002/hon.2517 · DOI
  56. Iurlo, 2018, Low-dose ponatinib in intolerant chronic myeloid leukemia patients: a safe and effective option, Clin Drug Investig., 38, 475, 10.1007/s40261-018-0623-7 · doi:10.1007/s40261-018-0623-7
  57. Levy, 2019, Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison, Curr Med Res Opin., 35, 479, 10.1080/03007995.2018.1510225 · doi:10.1080/03007995.2018.1510225
  58. Cerveira, 2018, Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report, BMC Cancer., 18, 1229, 10.1186/s12885-018-5100-4 · doi:10.1186/s12885-018-5100-4
  59. Kantarjian, 2011, Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial, Lancet Oncol., 12, 841, 10.1016/S1470-2045(11)70201-7 · DOI · Paper page
  60. Apperley, 2015, Chronic myeloid leukaemia, Lancet Lond Engl., 385, 1447, 10.1016/S0140-6736(13)62120-0 · DOI · Paper page
  61. Steegmann, 2016, European leukemianet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia, Leukemia., 30, 1648, 10.1038/leu.2016.104 · DOI · Paper page
  62. Sakurai, 2019, Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia, Int J Hematol., 109, 292, 10.1007/s12185-019-02596-z · DOI
  63. Cortes, 2017, Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management, Clin Lymphoma Myeloma Leuk., 17, 78, 10.1016/j.clml.2016.09.012 · DOI
  64. Hughes, 2019, Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for philadelphia chromosome-positive leukemia, Haematologica., 104, 93, 10.3324/haematol.2018.188987 · DOI
  65. Rousselot, 2014, Dasatinib daily dose optimization based on residual drug levels resulted in reduced risk of pleural effusions and high molecular response rates: final results of the randomized OPTIM DASATINIB trial, Haematologica., 99, 237
  66. Iurlo, 2018, Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life italian multicenter series, Ann Hematol., 97, 95, 10.1007/s00277-017-3144-1 · DOI
  67. Montani, 2012, Pulmonary arterial hypertension in patients treated by dasatinib, Circulation., 125, 2128, 10.1161/CIRCULATIONAHA.111.079921 · DOI · Paper page
  68. Weatherald, 2017, Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study, Eur Respir J., 50, 10.1183/13993003.00217-2017 · DOI
  69. Iurlo, 2015, Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?, Oncotarget., 6, 33944, 10.18632/oncotarget.5580 · DOI
  70. Cortes, 2016, Long-term evaluation of cardiac and vascular toxicity in patients with philadelphia chromosome-positive leukemias treated with bosutinib, Am J Hematol., 91, 606, 10.1002/ajh.24360 · DOI · Paper page
  71. Cortes, 2017, Effects of bosutinib treatment on renal function in patients with philadelphia chromosome-positive leukemias, Clin Lymphoma Myeloma Leuk., 17, 684, 10.1016/j.clml.2017.06.001 · DOI
  72. Jain, 2019, Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs, Blood Adv., 3, 851, 10.1182/bloodadvances.2018025874 · DOI
  73. Caocci, 2019, Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the systematic coronary risk evaluation (SCORE) chart, Hematol Oncol., 10.1002/hon.2606 · DOI
  74. Heiblig, 2018, Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study, Exp Hematol., 67, 41, 10.1016/j.exphem.2018.08.006 · DOI
  75. Kwak, 2017, Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia, Clin Cancer Res Off J Am Assoc Cancer Res., 23, 7180, 10.1158/1078-0432.CCR-17-0957 · DOI · Paper page
  76. Au, 2009, Chronic myeloid leukemia in Asia, Int J Hematol., 89, 14, 10.1007/s12185-008-0230-0 · DOI
  77. Horikoshi, 2003, Effects of lower dose of imatinib to CML patients, Leuk Res., 27, 1167, 10.1016/S0145-2126(03)00101-2 · doi:10.1016/s0145-2126(03)00101-2
  78. Eadie, 2018, The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro, Oncotarget., 9, 13423, 10.18632/oncotarget.24393 · DOI
  79. Schoepfer, 2018, Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1, J Med Chem., 61, 8120, 10.1021/acs.jmedchem.8b01040 · DOI · Paper page
  80. Hughes, 2016, Expanded phase 1 study of ABL001, a potent, allosteric inhibitor of 619 BCR-ABL, reveals significant and durable responses in patients with CML-chronic phase with 620 failure of prior TKI therapy, Blood., 128, 625, 10.1182/blood.V128.22.625.625 · DOI
  81. Rea, 2018, Asciminib, a specific allosteric BCR-ABL1 inhibitor, in patients with chronic myeloid leukemia carrying the T315I mutation in a phase 1 trial, Blood., 132, 792, 10.1182/blood-2018-99-113609 · DOI

Cited by

See all 134

Metadata

Authors
García-Gutiérrez, V., & Hernández-Boluda, J. C.
Venue
Frontiers in Oncology
Published
2019-07-03
Volume
9
ISSN
2234-943X
Cited by
134
References
2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety. https://app.cochat.ai/papers/10.3389/fonc.2019.00603
The paper
García-Gutiérrez, V., & Hernández-Boluda, J. C. (2019). Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety. Frontiers in Oncology. https://doi.org/10.3389/fonc.2019.00603

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.